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Abstract
Background: Polyphyllin I (PPI), a bioactive phytochemical extracted from the Rhizoma of Paris polyphylla, has been
reported to exhibit anti-cancer activity. However, the detailed mechanism underlying this remains to be elucidated.
Methods: Cell viability and cell cycle distribution were measured using a 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) and flow cytometry assays, respectively. The expression of enhancer
of zeste homolog 2 (EZH2) mRNA was measured by quantitative real time PCR (qRT-PCR). Western blot
analysis was performed to examine the phosphorylation and protein expression of stress-activated protein
kinase/c-Jun N-terminal kinase (SAPK/JNK), p65, DNA methyltransferase 1 (DNMT1) and EZH2. Exogenous
expression of p65, DNMT1, and EZH2 were carried out by transient transfection assays. Promoter activity
of EZH2 gene was determined using Secrete-Pair Dual Luminescence Assay Kit. A xenografted tumor model
in nude mice and bioluminescent imaging system were used to further test the effect of PPI in vivo.
Results: We showed that PPI significantly inhibited growth and induced cell cycle arrest of non-small cell
lung cancer (NSCLC) cells in a dose-dependent manner. Mechanistically, we found that PPI increased the
phosphorylation of SAPK/JNK, reduced protein expression of p65 and DNMT1. The inhibitor of SAPK/JNK
(SP600125) blocked the PPI-inhibited p65 and DNMT1 protein expression. Interestingly, exogenously expressed
p65 overcame PPI-inhibited protein expression of DNMT1. Moreover, PPI reduced EZH2 protein, mRNA, and
promoter activity; overexpression of EZH2 resisted the PPI-inhibited cell growth, and intriguingly, negative
feedback regulation of SAPK/JNK signaling. Finally, exogenous expression of DNMT1 antagonized the PPI-
suppressed EZH2 protein expression. Consistent with this, PPI inhibited tumor growth, protein expression
levels of p65, DNMT1 and EZH2, and increased phosphorylation of SAPK/JNK in vivo.
Conclusion: Our results show that PPI inhibits growth of NSCLC cells through SAPK/JNK-mediated inhibition
of p65 and DNMT1 protein levels, subsequently; this results in the reduction of EZH2 gene expression. The
interactions among p65, DNMT1 and EZH2, and feedback regulation of SAPK/JNK by EZH2 converge on the
overall responses of PPI. This study reveals a novel mechanism for regulating EZH2 gene in response to PPI
and suggests a new strategy for NSCLC associated therapy.
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Background
Lung cancer is the most common type of malignancy
worldwide, and the leading cancer-related cause of death
of both men and women. The majority of lung cancers
are the non-small cell lung cancer (NSCLC) presented
with advanced stage [1]. Despite recent advances in clin-
ical and experimental studies in the treatment of lung
cancer, the prognosis still remains poor due to the un-
countable recurrence and metastasis [1, 2]. Therefore,
there is an urgent need to search new agents with min-
imal side effects and improved treatment efficacy. These
included components from Chinese medical herbal
plants; among those, polyphyllin I (PPI) may be one of
such candidates.
PPI, a bioactive phytochemical extracted from the Rhi-
zoma of Paris polyphylla, has been reported to possess
preclinical anticancer efficacy in various cancer types
[3–6]. PPI induced apoptosis and reversed epithelial
mesenchymal transition in human osteosarcoma cells
[7]. Also, PPI triggered cell apoptosis, and inhibited cell
growth via regulating caspase activation pathway, increas-
ing c-Jun expression and reducing differential gene, such
as phosphatidylinositol-4-phosphate 3-kinase catalytic
subunit type 2 beta (PIK3C2β) and wingless-type MMTV
integration site family member 5A (Wnt5A), expressions
in human ovarian cancer cells [5]. Moreover, one study
showed that PPI exhibited anti-tumor effect in NSCLC
cells in vitro and in vivo at least through induction of
apoptotic signaling [8]. Nevertheless, the underlying mo-
lecular mechanisms in targeting lung cancer remain
largely unknown.
Nuclear factor-kappaB (NF-kB), a key transcription
factor, is involved in critical mechanisms connecting to
inflammation, cancer occurrence, and progression,
among others. NF-kB is activated by a variety of extra-
cellular signals, and regulates the expression of a variety
of genes [9]. The constitutive NF-kB activity was found
in a larger numbers of human cancers due to the inflam-
matory microenvironment, various oncogenic mutations
and inactivation of tumor suppressors. Given the most
likely tumor promoting role, targeting NF-kB could be
beneficial in the prevention and treatment of various
types of tumors including lung cancer [10–13]. Surpris-
ingly, until now there are no studies demonstrating the
potential role of NF-kB and its downstream signaling in
mediating the therapeutic effects of PPI. Therefore, the
detailed function and relevant mechanism of this tran-
scription factor involving in the anti-cancer response of
PPI remains unknown.
DNA methyltransferases (DNMTs) catalyze the methy-
lation at cytosine-C5 mainly in a CpG dinucleotide con-
text. Among the four active members (DNMT1,
DNMT3A, DNMT3B, and DNMT3L), DNMT1 is the
most abundant one responsible for maintenance of the
DNA methylation pattern. However, the exact mechan-
ism of suppression of DNMT1 signaling is not eluci-
dated. Likely mechanisms include enzymatic inhibition,
reduced DNMT1 expression [14]. Overexpression of
DNMT1 has been shown in several cancers including
lung [15–18]. Inhibition of DNMTs reduced tumor for-
mation, at least in part through the increased expression
of tumor suppressor gene [19]. Thus, targeting DNMT1
could be a potential in the prevention and treatment of
cancers [20–23].
Enhancer of zeste homologue 2 (EZH2), a potential
epigenetic silencer of tumor suppressor genes, is fre-
quently highly expressed in a wide variety of human can-
cers [24]. Previous studies have showed that expression
of EZH2 was correlated with proliferation, differenti-
ation, progression and metastasis in several cancer types
including lung. Therefore, inhibition of EZH2 through
direct and indirect mechanisms, such as epigenetic acti-
vation of oncogenic signaling cascades and silencing of
tumor suppressor genes, could be an important ap-
proach for cancer treatment [21, 25–28]. Moreover, the
mechanistically interaction between EZH2 and DNMT1
regulated their downstream targets, thereby controlling
DNA methylation and/or transcriptional repressed
micoRNAs (miRNAs) expression, which contributed to
growth and progression in several cancer types [29, 30].
In this study, we demonstrated the inhibitory effect of
PPI on lung cancer cell growth through stress-activated
protein kinase/c-Jun N-terminal kinase (SAPK/JNK)-me-
diated inhibition of NF-kB subunit p65 and DNMT1
protein levels, subsequently; this resulted in the reduc-
tion of EZH2 gene expression.
Methods
Reagents and cell culture
Monoclonal antibodies specific to total SAPK/JNK and
the phosphor-form (thr183/tyr185), EZH2, DNMT1,
NF-kB/p65, p50 and SP600125 (JNK inhibitor) were
purchased from Cell Signaling Technology Inc. (Beverly,
MA, USA). Lipofectamine 3000 reagent was ordered
from Life Technologies (AB & Invitrogen, Carlsbad, CA,
USA). PPI was purchased from Chengdu Must Biotech-
nology (Chengdu, China). The 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) power was
purchased from Sigma Aldrich (St. Louis, Mo, USA).
Cell Cycle Staining Kit was obtained from MultiSciences
Biotech Co. (Hangzhou, China). Geneticin (G-418 Sul-
fate) was obtained from Life Technologies (Grand Island,
NY, USA). The D-luciferin was obtained from PerkinEl-
mer (Waltham, MA, USA). PC9, A549 NSCLC cells
were obtained from the Chinese Academy of Sciences
Cell Bank of Type Culture Collection (Shanghai, China).
The cells were cultured at 37 ° C in a humidified atmos-
phere containing 5 % CO2. The culture medium
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consisted of RPMI 1640 medium obtained from GIBCO,
Life Technologies (Grand Island, NY, USA) supple-
mented with 10 % (v/v) heat-inactivated fetal bovine
serum (Thermo Fisher Scientific Inc, Waltham, MA,
USA), 100 μg/ml streptomycin and 100 U/mL penicillin.
The medium of A549-luc was added G-418 sulfate at
concentration of 300 μg/mL. When cells reached 75 %
confluence, they were digested with 0.25 % trypsin for
passage for the following experiments. The PPI was dis-
solved in a small amount of dimethylsufoxide [DMSO,
maximum concentration, 0.1 % (v/v)], which was then
added to complete cell culture medium. Cells treated
with vehicle only (DMSO, 0.1 % in media) was served as
control.
Cell viability assay
Cell viability was measured using the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) method as described previously [31]. Briefly, the
cells were seeded into a 96-well plate at 5 × 103 cells/
well, and incubated at 37 °C with 5 % CO2 for 24 h
before treated with increasing concentrations of PPI for
up to 72 h. In separate experiments, NSCLC cells were
transfected with control, pCMV6-EZH2 for 24 h before
exposure of the cells to PPI for an additional 24 h. After-
wards, absorbance at 570 nm was determined through
the use of ELISA reader (Perkin Elmer, Victor X5,
Waltham, MA, USA). Cell viability (%) was calculated as
follows: (absorbance of test sample/absorbance of
control) × 100 %.
Cell cycle analysis
This procedure was reported previously [32]. In brief,
PC9 cells were cultured in 6-well culture plates at
3 × 105 cells/well and treated with increased doses of
PPI for 24 h. Afterwards, the cells were washed and
resuspended in PBS and incubated with 0.1 % sodium
citrate containing propidium iodide (PI) 0.05 mg and
50 μg RNase for 1 h at room temperature (RT). The
cells were washed and subjected to FACScalibur flow
cytometric analysis (FC500, Beckman Coulter, FL,
USA), and the proportion of cells within the G0/G1,
S, and G2/M phases of the cell cycle were analyzed
using the MultiCycle AV DNA Analysis software
(Phoenix Flow Systems, Inc. San Diego, CA, USA).
Invasion assay
The invasion ability was detected by the Transwell plate
(Corning, NY, USA) with 10 mm diameter and 8 μM pore
size polycarbonate membrane. In brief, the matrigel (BD
Bioscience, San Jose, CA, USA) was diluted to 8 folds,
which was injected into the upper chamber before the ex-
periment. The lower chamber was added with 500 μL of
cell culture medium with 20 % FBS. Afterward, A549 and
PC9 cells were diluted to 0.5 × 106/mL and pretreated
with PPI (0.8 μM), and added 200 μL cells suspension into
the upper chamber, then incubated cells at 37 °C in a 5 %
CO2 for 16 h. Non-migration cells were removed and
invaded cells were fixed with 4 % paraformaldehyde, and
stained with crystal violet. Absorbance at 570 nm was
determined through the use of ELISA reader (Perkin
Elmer, Victor × 5, Waltham, MA, USA). Pictures were
taken under 100× magnification and the number of in-
vaded cells was counted as percentage of control.
Transient transfection assays
The detailed procedure was reported previously [33].
Briefly, NSCLC cells were seeded at a density of
2.5 × 105 cells/well in 6-well dishes and grown to
60 % confluence. For each well, 2 μg of the control
or wild type pEZX-PG04-EZH2 promoter constructs
(purchased from GeneCopoeia, Inc., Rockville, MD,
USA) with or without 0.2 μg of the internal control se-
creted alkaline phosphatase (SEAP) were co-transfected
into the cells with the EndoFectin Max transfection
reagent. The preparation of cell extracts and measurement
of luciferase activities were determined using the Secrete-
Pair Dual Luminescence Assay Kit (GeneCopoeia, Inc.,
Rockville, MD, USA), and was normalized with SEAP
activity within each sample. In the separated experiment,
2 μg of the control (pCMV6) and expression constructs
containing Myc-DDK-tagged- or Myc/FLAG-tagged ORFs
of human DNMT1 or EZH2 obtained from OriGene
Technologies, Inc. (Rockville, MD, USA), the control
(pCMV4) and p65 overexpression vector (pCMV4-p65)
obtained from the Addgene (Plasmid #21966, Cambridge,
MA, USA) [34] at a final concentration of 2 μg/mL, were
transfected into the cells with the Lipofectamine 3000 re-
agent. Cells were incubated for 24 h at 37 °C, then treated
with PPI for the indicated time for all other experiments.
Quantitative real-time PCR (qRT-PCR)
A quantitative real-time-PCR (qRT-PCR) assay was de-
veloped for the detection of EZH2 transcript. The
primers used in this study were designed as follows:
EZH2 forward 5′- AATCAGAGTACATGCGACTGAG
A -3′; reverse 5′- GCTGTATCCTTCGCTGTTTCC -3′;
GAPDH forward 5′- AAGCCTGCCGGTGACTAAC -3′;
reversed 5′- GCGCCCAATACGACCAAATC -3′. qRT-
PCR was performed in a 20 μL mixture containing 2 μL of
the cDNA preparation, 10 μL 2 × SYBR Green Premix
ExTaq, and 10 μM primer on an ABI 7500 Real-Time PCR
System (Applied Biosystems, Grand Island, NY, USA).
The PCR conditions were as follows: 10 min at 95 °C,
followed by 40 cycles of 15 s at 95 °C, and 1 min at 60 °C.
Each sample was tested in triplicate. Threshold values
were determined for each sample/primer pair, the average
and standard errors were calculated. The relative
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expression levels of EZH2 were normalized to that of
GAPDH. The data were analyzed using the comparative
threshold cycle (2−ΔΔCT) method.
Western blot analysis
The detailed method was based on previous report [31].
The cell lysates containing same amount of protein were
separated on SDS polyacrylamide gels. Membranes
(Millipore, Billerica, MA, USA) were incubated with
antibodies against the total and phosphor-form SAPK/
JNK, p50, p65, EZH2 and DNMT1 (1:1000). The mem-
branes were washed and incubated with a secondary
antibody raised against rabbit IgG conjugated to horse-
radish peroxidase (Cell Signaling, Beverly, MA, USA),
followed by transferring to freshly made ECL solution
(Immobilon Western; Millipore, Billerica, MA, USA),
and documented the signals using the Gel Imagine Sys-
tem (Bio-Rad, Hercules, CA, USA).
Xenograft tumors and bioluminescent imaging
The experiments were performed according to the guide-
lines for the care and use of laboratory animals approved
by the Animal Care and Use Committee of Guangdong
Provincial Hospital of Chinese Medicine (the Ethics Ap-
proval Number 2014014) and the National Institutes of
Health guide for the care and use of Laboratory animals.
A total of 36 eight-week-old female nude mice obtained
from Guangdong Provincial Research Center for Labora-
tory Animal Medicine (Foshan, Guangdong, China) were
maintained at the Animal Center of Guangdong Provincial
Hospital of Chinese Medicine in a specific pathogen-free
environment with food and water provided. A549 NSCLC
cells carrying luciferase report gene (A549-Luc, obtained
from the Guangzhou Land Technology Co., Guangzhou,
China) (1 × 106 cells) in 100 μL PBS were injected sub-
cutaneously in the upper hind limb of mice. Xenografts
were allowed to grow for over one week when the
initial measurement was made with calipers. Mice
were randomly divided into control, low (1 mg/kg)
and high doses (3 mg/kg) of PPI group, which given
once a day by intraperitoneal injection for up to
27 days (n = 12/group).
For bioluminescence imaging (BLI) procedure, mice
were anesthetized by inhalation of 2 % isoflurane. The sub-
strate D-luciferin (Caliper Life Sciences, Hopkinton, MA,
USA) was injected into the peritoneal cavity with a dose of
150 mg/kg in approximately 100 μL. The intensity of BLI
signal was determined using the IVIS-200 Imaging System
(Xenogen/Caliper, Alameda, CA, USA). Tumor volume
measurements were calculated using the formula for an
oblong sphere: volume = (width2 × length). Quantification
of bioluminescence was reported as photons/sec. The body
weights of the mice were measured once a week. All mice
were euthanized on day 27 in accordance with the Guide
for the Care and Use of Laboratory Animals.
Immunohistochemistry procedures
Immunoperoxidase staining for p-SAPK/JNK, DNMT1,
p65, EZH2 proteins were performed on all tissues from
representative subjects (control, PPI-treated groups).
Briefly, the antigen was retrieved by citric acid buffer
(pH 6.0) and then immersed in 3 % H2O2 to inhibit en-
dogenous peroxidase activity, followed by incubation in
5 % bovine serum albumin to block nonspecific binding.
The sections were then incubated with primary antibodies
against p-SAPK/JNK (1:100), p65 (1:100), EZH2 (1:50),
DNMT1 (1:100) at 4 °C overnight and then incubated
with biotinylated secondary antibody (Beijing Zhongshan
Golden Bridge Biotechnology Co., Ltd. Beijing, China) for
10 min. Detection was made using the 3,3 -diaminobenzi-
dine according to the instructions (DAB kit, Beijing
Zhongshan Golden Bridge Biotechnology Co., Ltd. China).
Pictures were taken under 200× magnification. The im-
munostaining was evaluated by Image-Pro Plus6.0 image
analysis software (Media Cybernetics, lnc. Sliver Spring,
MD, USA) in at least five random high-power fields.
Statistical analysis
All data were expressed as mean ± SD of three independ-
ent experiments. Differences between groups were
assessed by one-way ANOVA and significance of differ-
ence between particular treatment groups was analysed
by Tukey’s Multiple Comparison Test for multiple com-
parison involved using GraphPad Prism software version
5.0 (GraphPad Software, Inc. La Jolla, CA, USA). The re-
sults in the most graphs were presented relative to the
control. Asterisks showed in the figures indicated signifi-
cant differences of experimental groups in comparison
with the corresponding control condition. P-values
<0.05 were considered statistically significant.
Results
PPI inhibited growth and induced cell cycle arrest of
human NSCLC cells
We first set up to detect the effect of PPI on cell growth
in human NSCLC cells A549 and PC9 by MTT assay. As
show in Fig. 1a, PPI decreased the cell viability in a
dose-dependent manner with effective dose ranges of
0.8–1.2 μM for up to 72 h treatment. The IC 50s were
1.78, 1.385 and 0.84 μM in A549 and 2.19, 1.64 and
1.32 μM in PC9, respectively.
We also examined the effect of PPI on cell cycle phase
distribution. We found that PC9 cells treated with
increased concentrations of PPI for 24 h resulted in in-
crease in the proportion of cells at G0/G1 phase, while the
proportion of cells at S phases were reduced (Fig. 1b) as
detected by flow cytometry. The above results indicated
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that PPI induced cell cycle arrest at G0/G1 phase in
NSCLC cells. Finally, cell invasion assays showed that PPI
decreased the ability of invasion compared to the control
untreated one in A549 and PC9 cells (Fig. 1c).
PPI increased phosphorylation of SAPK/JNK in a
time-dependent manner
SAPK/JNK signaling pathway was involved in cell growth
depending on the cell types and stimulus. We showed that
PPI increased phosphorylation of SAPK/JNK starting at 0.5
and 4 h, and continuing for up to 4 and 8 h in PC9 and
A549 cells, respectively (Fig. 2). Note that the expression of
total SAPK/JNK proteins had no significant changes after
PPI treatment.
PPI decreased protein expression levels of DNMT1 and
EZH2 through SAPK/JNK pathway
We also search for the potential molecular targets that
may involve in the inhibitory effect of PPI on cell growth.
Herein, we showed that PPI decreased DNMT1, the major
enzyme responsible for DNA methylation, which is highly
expressed in various tumors [35] and EZH2, a key compo-
nent of polycomb repressive complex 2 (PRC2) and a po-
tential epigenetic silencing of tumor suppressor genes,
protein expression levels in a dose-dependent fashion in
A549 and PC9 cells (Fig. 3a). Moreover, PPI reduced
EZH2 mRNA levels and promoter activity as determined
by qRT-PCR and Dual Luminescence assays (Fig. 3b–c) in
A549 and PC9 cells. Next, to examine the role of SAPK/
JNK signaling in this process, we used specific inhibitors
of SAPK/JNK to pre-treated cells. As shown in Fig. 3d, the
inhibitor of SAPK/JNK (SP600125) significantly abolished
PPI-reduced DNMT1 and EZH2 protein expression levels.
This result indicated that activation of SAPK/JNK was in-
volved in the PPI-inhibited protein expression levels of
DNMT1 and EZH2.
Activation of SAPK/JNK pathways-mediated inhibition of
p65 expression contributed to the PPI-decreased protein
expression levels of DNMT1
NF-kB is a key inflammatory transcription factor fre-
quently expressed in cancers. In this study, we further
Fig. 1 PPI inhibited growth and induced cell cycle arrest of human NSCLC cells. a Lung cancer cell lines (PC9 and A549) were treated with increased
concentrations of polyphyllin (PPI) for up to 72 h. Afterwards, the cell viability was determined using the MTT assay as described in the Materials and
Methods section. b PC9 cells were treated with increased concentrations of PPI for up to 48 h. Afterwards, the cells were collected and processed for
analysis of cell cycle distribution by flow cytometry. The percentages of the cell population in each phase (G0/G1, S and G2/M) were assessed by
Multicycle AV DNA Analysis Software. c PC9 and A549 cells were treated with 0.8 μM PPI for up to 24 h. Shown are representative images of fixed and
crystal violet-stained PC9 and A549 cell invasion on the matrigel-coated inserts in the presence of vehicle (Con), and polyphyllin (PPI). Values are given
as the mean ± SD from 3 independent experiments and expressed as a percentage of total cells. Scale bar 100 μM. *Indicates significant difference as
compared to the untreated control group (P < 0.05). **Indicates significant difference from PPI treated alone (P < 0.05)
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explore the functional relevance of DNMT1 expression
after activation of SAPK/JNK. We found that PPI de-
creased protein expression levels of NF-kB subunit p65,
but had no effect on p50 protein (Fig. 4a) suggesting the
specificity of PPI. Interestingly, the inhibitor of SAPK/
JNK (SP600125) blocked this effect (Fig. 4b). Moreover,
exogenously expressed p65 showed to overcame PPI-
decreased protein expression levels of DNMT1 and
EZH2 (Fig. 4c). Together, the above results indicated
that SAPK/JNK signaling pathway was involved in inhib-
ition of p65 protein expression; the latter was contrib-
uted to the PPI-decreased protein expressions of
DNMT1 and EZH2.
Exogenously expressed EZH2 not only restored cell
growth, but also feedback antagonized PPI-increased
SAPK/JNK signaling
To further gain insight into the molecular mechanism by
which the interaction of DNMT1 and EZH2 contributed
to the overall response of PPI in this setting, we trans-
fected the DNMT1 and EZH2 expression plasmids into
the cells, separately. As shown in Fig. 5a–b, overexpres-
sion of DNMT1 reversed PPI- decreased EZH2 protein
expression levels, on the contrary, exogenous expression
of EZH2 had no effect on DNMT1 protein expression.
However, exogenous expressed EZH2 could resist PPI-
decreased cell growth (Fig. 5c). Intriguingly, it also antago-
nized PPI-stimulated phosphorylation of SAPK/JNK
(Fig. 5d). The above findings suggested the potential inter-
actions of DNMT1 and EZH2, and a negative feedback
regulation loop of SAPK/JNK by EZH2 in this process.
Anti-tumor effects of PPI in xenograft model
In order to prove the results in vitro, we tested the
effect of PPI in lung cancer xenograft mice model.
Mice bearing xenografted lung tumors were treated
with control or PPI [8] via intraperitoneal injection
for up to 27 days, followed by intraperitoneal injec-
tion of D-luciferin. We showed that, compared to the
control group, the high doses of (3 mg/kg) PPI-
treated mice demonstrated a significant growth-
inhibitory effect as assessed by the Xenogen IVIS200
System (Fig. 6a). In addition, we found a significant
reduction of the tumor weight and sizes (volume) in
the high dose of PPI-treated group as compared to
the control group (Fig. 6b–c). Moreover, consistent
Fig. 2 PPI increased phosphorylation of SAPK/JNK in a time-dependent manner. A549 and PC9 cells were treated with PPI (1.6 μM) in
the indicated times, and cell lysate was harvested and the expression of phosphorylated or total protein of SAPK/JNK were measured
by Western blot. GAPDH was used as loading control. Values in bar graphs were given as the mean ± SD from three independent experiments.
*Indicates significant difference as compared to the untreated control group (P < 0.05)
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with the results from the in vitro data, the induced
phosphorylation of SAPK/JNK, whereas reduction of
p65, DNMT1 and EZH2 protein expression levels
from fresh tumors harvested from the aforemen-
tioned experiment were observed in the high dose
PPI-treatment group as compared to that in the
control one using Western Blot and Immunohisto-
chemistry stain (Fig. 6d–e). Note that the low doses
of PPI treatment had no significant effects (not
shown).
Discussion
Previous studies showed that natural medicine such as
PPI could be considered as a potential agent for the
treatment of human cancers. However, the current data





Fig. 3 PPI decreased protein expression of DNMT1 and EZH2 through SAPK/JNK pathway. a PC9 and A549 cells were exposed to increased
concentration of PPI for 24 h. Afterwards, the expression of EZH2 and DNMT1 protein were detected by Western blot. b PC9 and A549 cells were
exposed to PPI (1.6 μM) for 24 h, followed by measuring the mRNA levels by qRT-PCR. c PC9 and A549 cells were transfected with a wild type
human EZH2 promoter reporter construct ligated to luciferase reporter gene and internal control for 24 h, followed by treating with PPI for an
additional 24 h. Afterwards, the promoter activities were determined using the Secrete-Pair Dual Luminescence Assay Kit as described in the
Materials and Methods Section. Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate.
d PC9 and A549 cells were treated with SP600125 (20 μM) for 2 h before exposure of the cells to PPI (1.6 μM) for an additional 24 h. Afterwards,
the expression of EZH2 and DNMT1 protein were detected by Western blot using antibodies against EZH2 and DNMT1. The bar graphs represent
the mean ± SD of EZH2 or DNMT1/GAPDH of three independent experiments. *Indicates significant difference as compared to the untreated
control group (P < 0.05). **Indicates significant difference from PPI treated alone (P < 0.05)
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cancer activity of PPI have not been well elucidated. In
this study, we demonstrated significant cytotoxicity and
cell growth inhibition in two NSCLC cell lines confirm-
ing the consistence of our findings and further strength-
ened the hypothesis. This also suggested the possibility
of anti-lung tumor activity of PPI. The concentrations of
PPI used in this study found to significant inhibit cell
viability and induce cell cycle arrest in a dose-dependent
manner were consistent, or even low with other studies
[3, 7, 8]. Mechanistically, our results indicated that the
activation of phosphorylation of SAPK/JNK signaling,
regulation and interaction between p65, DNMT1, and
EZH2 protein/gene were involved in the anti-lung can-
cer effect of PPI in this process.
Kinase signaling pathway such as PI3K/AKT/mTOR




Fig. 4 Activation of SAPK/JNK pathway-mediated inhibition of p65 expression contributed to the PPI-decreased protein expression of DNMT1.
a PC9 and A549 cells were exposed to increased concentration of PPI for 24 h, followed by measuring the protein expression of p65 and p50 by
Western blot. The bar graphs represent the mean ± SD of p65/GAPDH of three independent experiments. b PC9 and A549 cells were treated with
SP600125 (20 μM) for 2 h before exposure of the cells to PPI (1.6 μM) for an additional 24 h. Afterwards, the expression of phosphorylation of
SAPK/JNK and p65 protein were detected by Western blot. c PC9 and A549 cells were transfected with control and p65 overexpression vector for
24 h before exposing the cells to PPI for an additional 24 h. Afterwards, p65 and DNMT1 protein expressions were determined using Western blot.
Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate. *Indicates significant difference
as compared to the untreated control group (P < 0.05). **Indicates significant difference from PPI treated alone (P < 0.05)
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autophagy in human hepatocellular carcinoma (HCC)
cells [6]. In this study, our results suggested that activa-
tion of MAPK family member SAPK/JNK was directly
involved in the inhibitory effect of PPI in lung cancer
cells. Activation of SAPK/JNK signaling pathway has
been reported to regulate the expression of numerous
genes associated with apoptosis, invasion, metastasis and
survival [21, 36, 37]. We previously found that ursolic
acid, a pentacyclic triterpenoid, inhibited growth of
NSCLC cells through SAPK/JNK-mediated inhibition of
SP1; which in turn resulted in inhibition the protein ex-
pression levels of DNMT1 and EZH2 [21]. Fucoxanthin,
a marine carotenoid found in brown algae, showed to
suppress proliferation and induce cell cycle arrest
through SAPK/JNK-mediated induction of DNA
damage-inducible protein 45 (GADD45) gene in prostate
cancer cells [38]. However, opposite results also have
been reported [39], one study showed that blockade of
SAPK/JNK signaling was involved in the inhibition of
matrix metalloproteinase 9 (MMP9) expression in hu-
man gastric cancer cells by a natural compound [40].
Moreover, early study from SAPK/JNK gene deletion
experiment in different mouse models demonstrated
conflicting results regarding the pro-oncogenic and
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Fig. 5 Exogenously expressed EZH2 not only restored cell growth, but also feedback antagonized PPI increased SAPK/JNK signaling. a PC9 and
A549 cells were transfected with the control or expression constructs of DNMT1 for 24 h before exposing the cells to PPI for an additional 24 h.
Afterwards, EZH2 and DNMT1 protein expression were determined using Western blot. b–c PC9 and A549 cells were transfected with the control
or expression constructs of EZH2 for 24 h before exposing the cells to PPI for an additional 24 h. Afterwards, EZH2 and DNMT1 protein expression
(b) and cell viability (c) were determined using Western blot and MTT assays, respectively. d PC9 and A549 cells were transfected with the control
or expression constructs of EZH2 for 24 h before exposing the cells to PPI for an additional 24 h. Afterwards, EZH2, phosphor-SAPK/JNK were
determined using Western blot. Values in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate.
*Indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from PPI treated
alone (P < 0.05)
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Fig. 6 Effects of PPI in subcutaneous xenograft model. Mice (n = 12/group) were divided to 3 groups [Con (saline), Low (L, 1 mg/kg) and High
(H, 3 mg/kg)], and PPI was given by intraperitoneal injection for up to 27 days. a The xenografts were assessed by in vivo bioluminescence
imaging at the sixth and end of the experiments (on day 6 and 27). The tumor growth was monitored by injecting luciferin in the mice followed
by measuring bioluminescence and analyzed as described in the Materials and Methods section. Representative images are shown. b and c The
xenografts were harvested on day 27, and the size and weight of tumors were determined. The bar graphs represented the tumor weight and
size of mice results of as mean ± SD. d–e At the end of the experiments, xenografted tumors were isolated from individual animals and the
corresponding lysates were detected p-SAPK/JNK, DNMT1, p65 and EZH2 proteins by Western blot and Immunohistochemistry as described in
the Materials and Methods sections. Scale bar 50 μM. GAPDH was used as loading control for Western blot. Values in bar graphs were given as
the mean ± SD from three independent Western blot experiments. *Indicates the significant difference from untreated control (p < 0.05). f The
diagram shows that PPI inhibits growth of NSCLC cells through SAPK/JNK-mediated inhibition of p65 and DNMT1, subsequently; this results in
the reduction of EZH2 gene expression. The interactions among p65, DNMT1 and EZH2, and feedback regulation of SAPK/JNK by EZH2
converge on the overall responses of PPI
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tumor suppressor roles [41]. Thus, the potential dual
roles of this kinase may exist dependent upon the envir-
onmental context. More studies, such as siRNAs and
overexpression of the constitutive active form of kinase,
are needed to characterize the true role of SAPK/JNK in
mediating tumor growth.
Our study suggested the involvement of the inhibition
of DNMT1 and EZH2 in mediating the effect of PPI on
the inhibition of NSCLC cell proliferation. As critical
epigenetic and oncogenetic factors, increased expres-
sions of DNMT1 and EZH2 have been shown in several
cancer types including lung through silencing tumor
suppressor genes via hypermethylation and other mech-
anisms [42–45]. In addition, expression of DNMT1 and
EZH2 were associated with induced proliferation and
aggressive metastasis behavior of cancer cells resulting
in poor prognosis. Thus, targeting DNMT1 and EZH2
may be of therapeutic benefits for patients with some
malignancies [46–48]. Our results also implied the up-
stream role of SAPK/JNK signaling in the effect of PPI
on inhibition of DNMT1 and EZH2. Limited data have
been indicated the true links of this kinase signaling
to DNMT1 or EZH2 expression or methylation. Early
study indicated that the specific inhibitors or siRNA-
mediated knockdown of SAPK/JNK decreased DNMT1
expression, thereby inhibiting growth in colon cancer
cells [49]. Consistent with ours, one study reported that
mitogen-activated protein kinase (MAPK) pathway, such
as SAPK/JNK, mediated the down-regulation of EZH2,
thereby suppressing growth of breast cancer cells by cur-
cumin [50]. However, another report found that arsenic
induced EZH2 phosphorylation through JNK, signal
transducer and activator of transcription 3 (STAT3) and
Akt signaling pathways in human bronchial epithelial
cells [51]. The discrepancy remains unclear; different
stimuli, cell lines used and environmental contexts may
be accounting for this, which need to be determined
with more in-depth experimental approaches. We
believed that our findings provided the novel insight into
the connection between SAPK/JNK signaling and
expression of DNMT1 and EZH2 affected by PPI, and
also highlighted the tumor suppressor role of SAPK/JNK
that was involved in the anti-tumor effects of PPI.
We also demonstrated a possibility of NF-kB signaling
in this process. Our results suggested that inhibition of
one of NF-kB subunits p65 protein levels contributed to
the PPI-decreased protein expression of DNMT1. One
study showed that, nucleolin, an abundant multifunc-
tional phosphoprotein overexpressed in human malig-
nancies, increased DNMT1 gene expression via NF-kB
signaling. Inactivation or silencing of NF-kB diminished,
whereas exogenous expressed NF-kB increased promoter
activity and gene expression of DNMT1 in human
leukemia cells demonstrating nucleolin-NF-kB-DNMT1
axis as a new molecular pathway implicated in
leukemogenesis [52]. Also, dietary supplements such as
curcumin showed to increase G0/G1 cell cycle arrest
and induce apoptosis through inhibition of DNMT1 and
p65; this resulted in decrease in p65 binding to the
DNMT1 promoter implying therapeutic potential of cur-
cumin as an adjuvant treatment in acute myelocytic
leukemia [53]. The enhanced NF-kB activity is believed
to be highly associated with carcinogenesis. Thus, target-
ing NF-kB and its relevant signaling may involve in the
anti-cancer mechanism of PPI. As EZH2 is also a direct
NF-kB target gene [54], whether PPI–inhibited NF-ĸB/
p65 signaling had directly effect on EZH2 expression in-
dependent of DNMT1 needs to be determined. Never-
theless, more experimental data are required to further
elucidate this.
Furthermore, our study suggested that DNMT1 was
upstream of EZH2 and that interplay of DNMT1 and
EZH2 were responsible for the overall responses of PPI
in the inhibition of lung cancer cell growth. The cross-
talk and collaborative interaction between these two
molecules have been reported in other studies [55, 56],
and this may account for some of the oncological prop-
erties of EZH2 [29]. One study showed that inhibition of
DNMT1 not only decreased EZH2 binding to the pro-
moter regions of cyclin dependent kinase (CDK) inhibi-
tors but also reduced EZH2 expression in human
umbilical cord stem cells [57]. Thus, the true role and
mechanisms involved in this interaction need to be fur-
ther elucidated.
Furthermore, we for the first time demonstrated a
negative feedback regulation of SAPK/JNK signaling by
EZH2 implying that more complicated regulatory loops
were involved in the overall effects of PPI. While less
data was available for the feedback regulation of SAPK/
JNK signaling pathway by EZH2, the potential signifi-
cance of these regulatory mechanisms involved in the
overall responses of PPI required to be determined.
More importantly, our in vivo data were consistent
with the findings from that in vitro, confirming the
effect of PPI on lung cancer growth inhibition and regu-
lation of SAPK/JNK, p65, DNMT1 and EZH2 protein
expression levels. The given doses of PPI were similar
with other study demonstrating the substantial anti-
tumor effects in the inhibition of human lung cancer [8].
Nevertheless, more experiments are needed to elucidate
the precise role of EZH2 in this process using cells stable
transfected with shRNA (short hairpin RNA) and expres-
sion vectors containing the coding region of EZH2 gene
in nude mice model.
Conclusion
Collectively, our results show that PPI inhibits growth of
NSCLC cells through SAPK/JNK-mediated inhibition of
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p65 and DNMT1 protein expression levels, subse-
quently; this results in the reduction of EZH2 gene
expression. The interactions among p65, DNMT1 and
EZH2, and the negative feedback regulation of SAPK/
JNK by EZH2 also converge on the overall response of
PPI (Fig. 6f ). This study reveals a novel mechanism for
regulating EZH2 gene expression in response to PPI and
suggests a new strategy for NSCLC associated therapy.
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